Dexin Medical Repeatedly Honored as a 'Zhejiang Unicorn Enterprise' in 2026 and Files IPO Prospectus

At the 10th "Everything Grows Conference" held on April 23,Valgen Medtech Once Again Named "Zhejiang Unicorn Enterprise" and "Hangzhou Unicorn Enterprise"As an innovative force in the field of atrioventricular valve interventional treatment, Valgen Medtech has received this honor for many consecutive years. This recognition highly affirms Valgen Medtech's innovative R&D capabilities and long-term professional expertise.

Valgen Medtech adheres to the clinical needs as the guide, transforming cutting-edge technology into tangible patient benefits: relying on the self-developed DragonFly™ Transcatheter Mitral Valve Clip System, it exports China's wisdom in atrioventricular valve interventional treatment to the world.

In 2025, DragonFly™ holds a 47.14% market share in China.(Source: "2025 Annual Report on Transcatheter Mitral Regurgitation Interventional Treatment")The new adjustable bend guiding sheath made its debut at the recently concluded Hangzhou Valve Conference; meanwhile, the clinical trials and R&D of new products such as tricuspid regurgitation treatment devices are also steadily accelerating, aiming to fill more clinical gaps.

Based on profound professional expertise, Valgen Medtech is further accelerating its globalization efforts. Currently, DragonFly™ has entered 12 key countries and regions worldwide. By promoting global academic exchanges among operators and eliminating technical barriers, Valgen Medtech is sharing China's standardized operational experience in complex atrioventricular valve interventions with the world, thereby advancing the development of global TEER procedures.

In the future, Valgen Medtech will continue to focus on the field of atrioventricular valve intervention, promoting high-quality development in the global atrioventricular valve intervention field with safer and more effective solutions.

———— Previous Review ————